OnKure Therapeutics (OKUR) Expected to Post Quarterly Earnings on Thursday

OnKure Therapeutics (NASDAQ:OKUR) is projected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect OnKure Therapeutics to post earnings of ($0.4067) per share and revenue of $0.17 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.23. On average, analysts expect OnKure Therapeutics to post ($1.47) EPS for the current fiscal year and ($1.15) EPS for the next fiscal year.

OnKure Therapeutics Trading Up 1.2%

OnKure Therapeutics stock opened at $2.63 on Thursday. The company has a market capitalization of $106.25 million, a P/E ratio of -0.75 and a beta of 0.12. The firm’s fifty day simple moving average is $2.96 and its 200-day simple moving average is $3.60. OnKure Therapeutics has a 1-year low of $2.01 and a 1-year high of $5.38.

Wall Street Analysts Forecast Growth

OKUR has been the subject of a number of recent research reports. HC Wainwright decreased their price objective on shares of OnKure Therapeutics to $21.00 and set a “buy” rating for the company in a report on Monday, July 20th. Oppenheimer reissued an “outperform” rating and set a $14.00 target price on shares of OnKure Therapeutics in a research report on Friday, August 14th. Finally, Weiss Ratings upgraded OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, OnKure Therapeutics has an average rating of “Hold” and a consensus target price of $17.50.

About OnKure Therapeutics

OnKure Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company’s research is centered on small-molecule therapies designed to target cancer-driving transcription factors and related proteins that are difficult to address with conventional drug approaches.

Its lead product candidate, OKN4395, is an oral small-molecule inhibitor of the EP300/CBP bromodomains. The program is being investigated as a potential treatment for solid tumors, including in combination with immune checkpoint inhibitors such as pembrolizumab.